<a href="https://laohu8.com/S/GYRE">Gyre Therapeutics</a> Subsidiary Completes Enrollment in Phase 3 Trial of Pirfenidone Capsules for Pneumoconiosis
Gyre Therapeutics Inc. announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd., has completed patient enrollment in a Phase 3 clinical trial of Pirfenidone capsules for the treatment of pneumoconiosis.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9545809-en) on October 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments